Clinical trial
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
NCT02404441
Study timeline
Study start (actual)2015-04-27Date precision: day
Registry last updated2022-08-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Non-small Sell Lung Cancer (NSCLC)unresolved
Triple Negative Breast Cancerunresolved
Anaplastic Thyroid Cancerunresolved
Other Solid Tumorsunresolved
Interventions
PDR001BIOLOGICAL
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02404441 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.